- METALLOENZYME INHIBITOR COMPOUNDS
-
Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
- -
-
Page/Page column 51
(2020/07/25)
-
- Development of Highly Selective Pyrimidine-Based Aldosterone Synthase (CYP11B2) Inhibitors
-
Excess aldosterone production and signaling are primary contributors to numerous cardiovascular disorders including primary aldosteronism and resistant hypertension. Recently, inhibition of aldosterone synthesis via the enzyme aldosterone synthase (CYP11B
- Sparks, Steven M.,Danger, Dana P.,Hoekstra, William J.,Leesnitzer, Tony,Schotzinger, Robert J.,Yates, Christopher M.,Becherer, J. David
-
supporting information
p. 1056 - 1060
(2019/06/25)
-
- METALLOENZYME INHIBITOR COMPOUNDS
-
Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
- -
-
Paragraph 0384; 0385; 0386
(2018/07/29)
-
- METALLOENZYME INHIBITOR COMPOUNDS
-
Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
- -
-
Paragraph 0532; 0533; 0534
(2018/07/29)
-
- Non-nucleoside reverse transcriptase inhibitors
-
Provided are compounds of the general formula I: wherein R2 is selected from the group consisting of H, F, Cl, (C1-4) alkyl, (C3-4) cycloalkyl and CF3; R4 is H or Me; R5 is H, Me or Et, wit
- -
-
-